Denali Therapeutics Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

DNLI$19.85-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2024	144,220,986	$1,768	$2,764,880	$2,020	$(1,538,984)	$1,229,684
Issuances under equity incentive plans	113,792	1	594	—	—	595
Vesting of restricted stock units	916,480	9	(9)	—	—	—
Stock-based compensation	—	—	25,360	—	—	25,360
Net loss	—	—	—	—	(132,970)	(132,970)
Other comprehensive income	—	—	—	17	—	17
Balance at March 31, 2025	145,251,258	$1,778	$2,790,825	$2,037	$(1,671,954)	$1,122,686
Balance at December 31, 2025	156,182,177	$1,888	$3,062,715	$682	$(2,051,524)	$1,013,761
Issuance of common stock, net of issuance cost of $45	746,468	8	12,358	—	—	12,366
Issuances under equity incentive plans	536,720	5	6,690	—	—	6,695
Vesting of restricted stock units	1,190,953	12	(12)	—	—	—
Stock-based compensation	—	—	23,087	—	—	23,087
Net loss	—	—	—	—	(128,447)	(128,447)
Other comprehensive loss	—	—	—	(1,364)	—	(1,364)
Balance at March 31, 2026	158,656,318	$1,913	$3,104,838	$(682)	$(2,179,971)	$926,098

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.